Business
FTSE 100 climbs on strong retail sales data
Stock prices in London closed higher on Friday, as a swathe of domestic economic data was well-received and the US Supreme Court ruled President Donald Trump’s tariff programme is illegal.
The FTSE 100 index closed up 59.85 points, 0.6%, at 10,686.89.
The FTSE 250 ended up 178.07 points, 0.8%, at 23,751.56, and the AIM all-share closed up 3.97 points, 0.5%, at 815.11.
In European equities on Friday, the CAC 40 in Paris closed up 1.4%, while the DAX 40 in Frankfurt ended 0.9% higher.
The pound climbed to 1.3492 dollars on Friday afternoon from 1.3455 dollars at the equities close on Thursday.
The euro stood slightly higher at 1.1780 dollars from 1.1768 dollars.
Against the yen, the dollar was trading marginally higher at 154.95 yen compared to 154.90 yen.
The US Supreme Court ruled that President Donald Trump exceeded his authority in imposing a swathe of tariffs that upended global trade, blocking a key tool the president has wielded to impose his economic agenda.
The conservative-majority high court ruled six-three in the judgment, saying the International Emergency Economic Powers Act “does not authorise the president to impose tariffs”.
While Mr Trump has long used tariffs as a lever for pressure and negotiations, he made unprecedented use of emergency economic powers upon returning to the presidency last year to slap new duties on virtually all US trading partners.
These included “reciprocal” tariffs over trade practices that Washington deemed unfair, alongside separate sets of duties targeting major partners Mexico, Canada and China over illicit drug flows and immigration.
The court on Friday noted that “had Congress intended to convey the distinct and extraordinary power to impose tariffs” with IEEPA, “it would have done so expressly, as it consistently has in other tariff statutes”.
The ruling does not impact sector-specific duties that Mr Trump has separately imposed on imports of steel, aluminium and various other goods.
Formal probes which could ultimately lead to more such sectoral tariffs remain in the works.
“The Supreme Court ruling on Trump’s tariffs will unlikely be a big game changer for markets,” said Ebury analyst Matthew Ryan.
“Not only was the decision broadly expected, but the president has already signalled that he will quickly pivot to other legal tools to achieve similar trade restrictions, and he has at his disposal multiple levers to pull in order to circumvent the verdict.”
“This means that while we could see some near-term disruption, his long-term tariff strategy is unlikely to be derailed so long as the White House can replicate the regime through alternative methods.”
Meanwhile, Mr Trump said he is contemplating a limited military strike on Iran, in case a deal on its nuclear programme is not reached.
Asked by a reporter if he is “considering a limited military strike if Iran doesn’t make a deal,” Mr Trump answered: “The most I can say – I am considering it.”
Back in the UK, a torrent of positive economic data was in focus.
Analysts said positive retail sales and purchasing managers’ index data for the UK provided further evidence that economic activity picked up in the new year as uncertainty from the Government autumn budget faded.
Retail sales increased 1.8% on-month in January, compared with a 0.4% rise in December and far outstripping the consensus forecast for a 0.2% rise.
The flash UK purchasing managers’ composite output index rose to a 22-month high of 53.9 points in February from 53.7 in January, beating the FXStreet-cited market consensus of 53.4 points, which would have meant a deceleration of growth.
Climbing further above the neutral 50-point mark separating growth from contraction, it indicates the pace of activity accelerated in February.
“Retail sales provide further evidence that economic activity is picking up smartly in the new year as budget uncertainty fades,” said Pantheon Macroeconomics analyst Rob Wood.
Stocks in New York were higher.
The Dow Jones Industrial Average was slightly higher, the S&P 500 index was up 0.4%, and the Nasdaq Composite 0.8% higher.
The yield on the US 10-year Treasury widened slightly to 4.09% on Friday from 4.08% on Thursday.
The yield on the US 30-year Treasury widened to 4.73% from 4.71%.
US economic growth was slower than expected in the final quarter of the year, though separate numbers showed inflationary pressure picked up in December, giving the US Federal Reserve some food for thought.
Gross domestic product rose 1.4% on an annualised basis quarter-on-quarter, the Bureau of Economic Analysis said, slowing from a 4.4% rise in the third quarter, and below FXStreet cited expectations of a 3.0% rise.
“The contributors to the increase in real GDP in the fourth quarter were increases in consumer spending and investment. These movements were partly offset by decreases in government spending and exports. Imports, which are a subtraction in the calculation of GDP, decreased,” the BEA said.
Back in London, Diageo ended 3.9% higher and led the FTSE 100 after the Financial Times reported Dave Lewis, who took over as chief executive at the start of this year, is planning major changes to his executive team.
Mr Lewis, who earned a reputation for cost-cutting as chief executive of UK grocer Tesco, wants to change the “fat and happy” culture at brewer and distiller Diageo, the newspaper said, citing “two people familiar with the matter”.
This will include replacing several members of the 14-person executive committee, the people told the FT.
Segro closed up 2.0% after it reported a decline in pre-tax profit for 2025, despite increased revenue, as lower valuation gains offset record rental income.
The London-based property developer reported £560 million in pre-tax profit for 2025, down 12% from £636 million in 2024.
Adjusted pre-tax profit, which strips out property valuations, increased 8.3% to £509 million from £470 million.
The weaker earnings amid the improved top line are owed to smaller realised and unrealised property gains, down 72% at £55 million, compared to £195 million a year earlier.
On the FTSE 250 index, TBC Bank closed up 7.0% as it said a positive final quarter of 2025 helped it reach strong full-year results, allowing for a double-digit increase in its annual dividend.
Pretax profit was 1.67 billion Georgian lari in 2025, up 8.4% from 1.54 billion lari in 2024, as total income before credit loss provisions and expenses rose 20% to 3.39 billion lari from 2.83 billion lari.
Within that, net interest income was 2.35 billion lari in 2025, up 24% from 1.90 billion lari in 2024.
TBC Bank declared a final dividend of 3.87 lari per share for a total dividend for 2025 of 8.87 lari per share, up 10% from 2024 and representing a payout ratio of 35%.
TBC also carried out a 75 million lari share buyback programme last year.
Aston Martin Lagonda shares closed down 1.4% after it issued a profit warning as it noted the impact of “heightened tariffs” in the US.
The Warwickshire-based luxury car maker said it expects to report a gross margin for 2025 of around 29.5%, down from 36.9% in 2024.
Aston Martin also anticipates adjusted earnings before interest and tax “slightly below” the lower end of the analyst expectations of a £184 million loss, widening from a £82.8 million loss.
Looking ahead, Aston Martin said it expects a “material improvement” in its 2026 financial performance.
This expectation is driven by a combination of an enhanced product mix, ongoing benefits from its transformation programme and a “continued disciplined approach to operations”.
On the AIM market, SkinBioTherapeutics closed 8.9% higher.
The stock has fallen 2.0% this week.
The Newcastle Upon Tyne-based life sciences firm said non-executive director Alyson Levett will oversee an independent investigation of the events that led to the departure of Stuart Ashman as chief executive officer.
Ms Levett, who chairs the board’s audit committee, will work with FRP Advisory, which the board has engaged to undertake a “forensic review”.
On Monday, SkinBioTherapeutics said Mr Ashman “misrepresented material information to the board, senior management, auditors and advisors” regarding accrued royalty income reported for the financial year that ended in June last year.
The resulting removal of £770,000 in accrued royalty income will reduce financial 2025 revenue to £3.9 million from the previously reported £4.6 million.
The stock has fallen 19% this week.
Brent oil was slightly lower at 71.33 dollars a barrel on Friday afternoon from 71.71 dollars late on Thursday.
Gold climbed to 5,066.90 dollars an ounce from 5,003.14 dollars.
The biggest risers on the FTSE 100 were Diageo, up 69.0p at 1,850.5p, Antofagasta, up 143.0p at 4,018.0p, Burberry, up 35.5p at 1,210.0p, British American Tobacco, up 97.0p at 4,570.0p, and Lloyds Banking, up 2.0p at 104.0p.
The biggest fallers on the FTSE 100 were BP, down 11.08p at 467.92p, DCC, down 65.0p at 5,135.0p, Associated British Foods, down 18.5p at 1,958.0p, Mondi, down 8.4p at 926.6p, and Convatec, down 1.8p at 228.8p.
On Monday’s global economic data are US factory orders figures and a reading on Germany’s business climate.
On the corporate slate for Monday are full year results from Mony Group, with major results due later in the week from HSBC, Diageo and Rolls-Royce among others.
– Contributed by Alliance News
Business
Greggs launches chicken version of sausage and vegan rolls in ‘iconic trilogy’
Greggs is launching a chicken version of its customer favourite sausage and vegan rolls in a permanent addition to its menu.
The Chicken Roll – described by the high street baker as “seasoned chicken wrapped in layers of crisp, golden, glazed puff pastry” contains 305 calories and will cost £1.35 when it goes on sale on Thursday.
It follows the Sausage Roll and the pork free Vegan Roll.
To celebrate the final launch of the “trilogy”, Greggs is allowing customers the chance to be among the first to taste the new roll with a 20-minute slot between 3.30pm and 9pm on Wednesday (April 8) at a pop-up location at 15 Bateman Street, in London’s Soho.
Places will be given on a first-come first-served basis but, in a nod to the trilogy theme, guests must arrive as part of a trio of friends or family.
Visitors will be able to pair their three complimentary rolls with a free chicken-themed cocktail or mocktail.
A Greggs spokeswoman said: “They say the best things come in threes, and our iconic roll trilogy is no exception.
“We can’t wait for our customers to experience the Chicken Roll as the ultimate headline act of our flaky franchise.”
Over the past year, Greggs has come under pressure from cautious shoppers affected by the rising cost of living, higher tax and labour costs, and the growing use of weight-loss treatments.
Last month, the Newcastle-based firm reported that statutory pre-tax profits fell by 17.9% to £167.4 million for the year to December 27, compared with a year earlier.
It also told shareholders that total sales grew by 6.8% to £2.15 billion over the year, with like-for-like growth buoyed by its continued store opening programme.
Greggs said it had 121 net store openings in 2025, expanding its shop estate to 2,739 locations by the end of the year.
It is targeting around 120 further openings this year as it highlighted ambitions to grow to “significantly more than 3,000 UK shops over longer term”.
Business
Wellness brand announces new product range for those on weight-loss jabs
Applied Nutrition is significantly expanding its product range to cater to customers using weight loss drugs, following a substantial increase in demand over the past year.
The health and wellness brand said it has identified a key business opportunity stemming from the sharp rise in Britons using GLP-1 treatments, such as Mounjaro and Wegovy.
The London-listed company, which already offers GLP-1-friendly high-protein ready meals launched in late 2025, confirmed that new products specifically designed for this market will be introduced later this year.
“The GLP-1 user is a growing customer. We see this as a consumer at the start of their weight loss journey who is now looking at how the medication can help them,” Thomas Ryder, founder and chief executive of the Liverpool-based firm, said.
“There is an opportunity, as those customers often need supplements and need smaller portions. I think this is a catalyst for the health and wellness space if we have that consumer in mind.
“We do have a number of products we will bring to market in this area because we do see that area growing.”
At least 1.6 million Britons have used weight loss jabs in the past year, according to research by University College London.
Applied Nutrition has reported strong growth, driven by targeting new customer opportunities and diversifying its sales channels, including expansion into UK retail stores.
In March, the company announced robust financial results, with pre-tax profits soaring by 77.1% to £20.9 million for the six months ending 31 January, compared to the previous year.
Sales also saw a significant uplift, rising by 56.5 per cent to £74.5 million over the same half-year period.
However, the firm cautioned that sales volumes in the Middle East are expected to be affected by the ongoing conflict in the region.
Applied Nutrition said it still expects to meet revenue targets for the year of around £140 million.
The company added: “Importantly, we have managed similar disruption in the past, supported by the agility of our operations.
“In this instance, we are working closely with customers to adapt our routes into the region and logistics arrangements to safeguard continued supply to those customers.”
Business
Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurers
Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks during an event sponsored by the Action for Progress Coalition, at the National Press Club in Washington, D.C., U.S., Feb. 2, 2026.
Al Drago | Reuters
The Trump administration on Monday finalized a 2027 payment rate increase to privately run Medicare plans that was far bigger than initially proposed, a boost to health insurer stocks.
The government will increase average Medicare Advantage payments by 2.48%, or more than $13 billion, in 2027, according to a release from the Centers for Medicare & Medicaid Services. The Trump administration in January proposed a payment rate hike of 0.09%, which pummeled shares of insurers that run those plans.
Shares of UnitedHealth and CVS Health rose more than 9% in after-hours trading on Monday. Meanwhile, Humana‘s stock jumped around 12%.
“Medicare Advantage and Part D should work for the people who rely on them,” said CMS Administrator Dr. Mehmet Oz in a release. “These updates keep coverage affordable and ensure patients get real value from their plans.”
The closely watched government payment rate determines how much insurers can charge for monthly premiums and plan benefits they offer and, ultimately, their profits.
Medicare Advantage is a privately run health insurance plan contracted by Medicare. More than half of Medicare beneficiaries are enrolled in such plans, enticed by lower monthly premiums and extra benefits not covered by traditional Medicare, according to health policy research firm KFF.
-
Sports1 week agoUSMNT handed reality check by Doku, Belgium ahead of World Cup
-
Uncategorized4 days ago
[CinePlex360] Please moderate: “Trump signals p
-
Sports1 week ago2026 NCAA men’s hockey tournament: Schedule, results
-
Tech3 days agoOur Favorite iPad Is $50 Off
-
Uncategorized1 week ago
[CinePlex360] Please moderate: “Further tariff
-
Entertainment3 days agoJoe Jonas shares candid glimpse into parenthood with Sophie Turner
-
Politics7 days agoTrump considers asking Arab allies to help to pay for Iran war
-
Entertainment1 week agoDemystifying the PTI
